Company: RGNX
Filing Date: 2025-06-13
Form Type: S-3
Source: 0001193125-25-140870
Chunk: 15

Company: REGENXBIO Inc.
Filing Date: 2025-06-13
Form: S-3
Chunk 15
---
 under the symbol “RGNX.”

Transfer Agent and Registrar

The
transfer agent and registrar for our common stock is Computershare Trust Company, N.A.

9

THE SELLING STOCKHOLDER We have prepared this prospectus to allow the Selling Stockholder to sell or otherwise dispose of, from time to time, up to 268,096 Shares of our common stock issuable upon the Selling Stockholder’s exercise of the Warrant at an exercise price of $14.92 per share, which Warrant was issued in connection with execution of a Loan Agreement, dated May 16, 2025, by and between REGENXBIO RS LLC, a wholly owned subsidiary of the Company, and an affiliate of HealthCare Royalty Management, LLC. We issued the Warrant on May 16, 2025 in a private placement conducted, in reliance upon Section 4(a)(2) of the Securities Act. The following table sets forth the identity of the Selling Stockholder, the number of Shares and the percentage of Shares beneficially owned by the Selling Stockholder and its affiliates prior to this offering, the number of Shares that may be offered under this prospectus by the Selling Stockholder, and the number of shares of our Common Stock and the percentage of our Common Stock to be beneficially owned by the Selling Stockholder and its affiliates after the completion of this offering, assuming that all Shares offered hereunder are sold by the Selling Stockholder as contemplated herein. The number of Shares in the column “Maximum number of shares that may be offered” represents all of the Shares that the Selling Stockholder may offer under this prospectus. For purposes of the table below, the beneficial ownership amounts and percentages are based on a total of 50,388,693 shares of our common stock outstanding as of June 9, 2025. Information about additional selling stockholders, if any, including their identities and the Shares to be registered on their behalf, may be set forth in a prospectus supplement, in a post-effective amendment or in filings that we make with the SEC under the Exchange Act, which are incorporated by reference in this prospectus. Information concerning the Selling Stockholder may change from time to time. Any changes to the information provided below will be set forth in a supplement to this prospectus, in a post-effective amendment or in filings we make with the SEC under the Exchange Act, which are incorporated by reference into this prospectus, if and when necessary.

|                             |     | Shares beneficially owned |         |